Tag - IFRX

Markets

SVB Leerink ups Inflarx to OP; PT to $10 from $7

SVB Leerink upgraded Inflarx (NASDAQ:IFRX) to “outperform” from “market perform” and raised its price target to $10 from $7, citing a “significant disconnect between the promise of IFX-1 in multiple applications, most...

November 6, 2020

Developments

InflaRx reports topline results from Phase 2/3 COVID-19 trial

InflaRx (NASDAQ:IFRX) reported encouraging topline results from the first 30 COVID-19 patients treated with IFX-1 in a Phase 2/3 trial. IFX-1 is a monoclonal anti-human complement factor C5a antibody designed to...

June 17, 2020

Developments

InflaRx IFX-1 misses primary endpoint in Phase 2b hidradenitis suppurativa trial

InflaRx (NASDAQ:IFRX) reported that IFX-1 missed its primary endpoint in a Phase 2b trial in hidradenitis suppurativa (HS) patients. HS a chronic inflammatory skin disease that causes abscesses and scarring. IFX-1 is a...

July 19, 2019

Markets

SVB Leerink ups InflaRx PT to $67 from $42

SVB Leerink raised its price target for InflaRx N.V. (NASDAQ:IFRX) to $67 from $42, citing a potentially larger orphan market for the company’s lead indication. The stock closed at $43.77 on April 9. “We have been...

April 10, 2019

Tag - IFRX

SVB Leerink ups Inflarx to OP; PT to $10 from $7

InflaRx reports topline results from Phase 2/3 COVID-19 trial

InflaRx IFX-1 misses primary endpoint in Phase 2b hidradenitis suppurativa trial

SVB Leerink ups InflaRx PT to $67 from $42

General

More